No abstract available.
Gonadal Dysgenesis, Mixed*

No abstract available.
Beckwith-Wiedemann Syndrome*

No abstract available.
Dermatitis, Atopic* ; Eczema* ; Kaposi Varicelliform Eruption*

No abstract available.
Autopsy* ; Cardiomyopathies* ; Humans ; Infant, Newborn*

No abstract available.
Mycoplasma pneumoniae* ; Mycoplasma* ; Pneumonia* ; Pneumonia, Mycoplasma*

Gastrointestinal symptoms are a frequent but usually underreported constituent of the clinical spectrum of Parkinson's disease (PD), and they contribute significantly to the disease-related morbidity and mortality. Virtually all parts of the gastrointestinal tract can be affected, even in the premotor stage. Weight loss, salivary excess, dysphagia, nausea/gastroparesis, constipation, and anorectal dysfunction can all occur. Gastrointestinal symptoms may result from the involvement of either the central or enteric nervous system in the disease process, or be a side effect of antiparkinsonian medications. Awareness of the various gastrointestinal manifestations of PD can facilitate the prompt recognition of and effective therapeutic intervention for these potentially distressing symptoms.
Constipation ; Deglutition Disorders ; Enteric Nervous System ; Gastrointestinal Tract ; Mortality ; Parkinson Disease* ; Weight Loss

No abstract available.
Dacarbazine* ; Gabexate*

No abstract available.
Acute Kidney Injury* ; Hepatitis* ; Humans ; Oxidoreductases*

PURPOSE: To evaluate the clinical effect of intravenous glutamine administration on patients admitted to the intensive care unit in general hospitals. METHODS: Patients with more than 7 days in an intensive care unit were evaluated. The experimental group was the patients who received intravenous glutamine administration for more than 3 days. The laboratory results, intensive care unit length of stay, hospital length of stay, 30 days mortality, and hospital mortality were evaluated with a comparative group. RESULTS: The mean number of administration days of intravenous glutamine was 10.12±8.93 days, and the average daily dose was 0.33±0.10 g/kg/day. No adequate improvement in the laboratory results of glutamine-treated group was observed. The intensive care unit length of stay (21.16±15.83 vs. 16.48±11.06, P=0.007), hospital length of stay (35.94±30.75 vs. 27.34±19.09, P=0.010), 30 days mortality (20.0% vs. 10.0%, P=0.034), and hospital mortality (26.3% vs. 13.0%, P=0.001) were higher in the glutamine-treated group. CONCLUSION: The use of intravenous glutamine on intensive care unit patients did not improve the clinical effect. Further large-scale multi-center studies will be needed to assess the proper administration of intravenous glutamine on intensive care unit patients.
Critical Care ; Glutamine ; Hospital Mortality ; Hospitals, General ; Humans ; Intensive Care Units ; Length of Stay ; Mortality

The effects of skeletal muscle relaxants on skeletal muscle have been well known, but not effects of those drugs on smooth muscle have intensively studied. In an attempt to study the effects of pancuronium, gallamine, succinylcholine and d-tubocurarine on isolated tracheal preparation of mongrel dog. The writters have performed a set of experiment, of which results can be summarized as follow: 1) Pancuronium in dose of 3ug, 10ugi 30ug, 100ug produced dose-dependent relaxation on contraction. 2) Gallamine in dose of 100ug, 300ug, 1,000ug and 3,000ug produced dose dependent relax histamine action on histamine contraction. 3) Succinylocholine in dose of 10ug, 30ug, 100ug and 300ug produced dose dependent contraction on histamine contraction. 4) d-Tubocurarine in dose of 30ug, 100ug, 300ug and 1,000ug produced dose dependent contraction on histamine contraction. From the results described above, it can be concluded that pancuronium and gallamine have bronchodilating character and succinylcholine and d-Tubocurarine have bronchospastic character.
Dogs ; Animals